Committed to helping you meet the evolving challenges and opportunities in patient care.

Supporting every aspect of your clinical practice, including physical exam, diagnostic cardiology, vitals monitoring and vision screening

Advancing products and technologies designed to speed patient recovery and streamline clinical workflows

Delivering innovations that enable reduced operating times, faster patient recovery and improved outcomes

Pioneering care in hemodialysis (HD), peritoneal dialysis (PD) and digital health to support better outcomes for your patients

Personalizing nutritional care designed to improve patients’ health in the hospital, the ICU and at home

Helping your patients with respiratory therapies designed to simplify delivery and improve mobility

Our portfolio of acute, nutritional, renal, hospital and surgical care products helps advance healthcare around the world.

For nearly a century, we have worked at the intersection of saving and sustaining lives.

Patients’ journeys inspire our work and drive our commitment.

We’re engaging with industry thought leaders to explore how science and innovation advance healthcare.

We are a community of diverse professionals working together to drive better healthcare options.

Enriching the communities where we live and work.

Our 90-year heritage gives us distinct perspective on the needs of patients and caregivers. We lead today by putting those insights to work to deliver new, better healthcare solutions and access to care in the communities where we live and work.

Our forward-looking leadership team is a driving force in ensuring we meet the needs of all our stakeholders – every day and everywhere.

We are proud of our strong commitment to maintaining the highest standards of corporate governance.

Nurturing a culture of innovation is critical to delivering on our mission to save and sustain lives. We partner with the healthcare community to continually find more efficient, smarter ways to help solve the world's most pressing healthcare challenges.

We strive to create lasting value by empowering our patients, protecting our planet and championing our people and communities.

We are committed to attracting, motivating and retaining an inclusive and diverse workforce.

For nearly a century, we’ve been focused on saving and sustaining lives and elevating patient care.

Helping you reach a healthy life, full of possibility.

Whether you are receiving care in the hospital, at your doctor’s office or at home, we are here to support every step of your journey.

When medical conditions prevent you from adequately feeding yourself, we provide life-saving clinical nutrition options to help you regain your nutritional status.

Kidney disease is an ongoing journey for you and your family. While every journey is unique, Baxter is committed to supporting access to care options to meet your medical and lifestyle needs.

We are committed to helping you with innovative products that deliver effective, proven respiratory therapy in the hospital and at home.

Across the continuum of kidney disease care, we are committed to leading access to insight-driven innovation and services so patients can live their best lives.

About 850 million people suffer from kidney disease globally. We estimate that as many as 10 million of them may have progressed to end-stage kidney disease and now require dialysis or transplant.1 Our focus is on helping you support greater access to care and better outcomes for your patients as they sequence through their therapy journey, knowing many patients transition between therapies as their disease progresses.

While your patient population is growing, your time and resources to care for them are not increasing. We understand you need innovative devices, digital health platforms and services to help you deliver better outcomes for more patients with your available resources.

We believe a patient’s sequence of care should begin at the early stages of chronic kidney disease, when there is time to educate them about their disease and potentially treat them before there is a need to initiate dialysis.

When end-stage kidney disease is reached, we also believe the next step should be to empower them to perform their care at home—typically on peritoneal dialysis (PD)—if the patient is clinically eligible for home care.

PD offers patients independence and control of their therapy due to portability, continued daily activities, reduced clinic visits and lower caregiver burden.2-6 Many PD patients can also maintain pre-dialysis activity levels, enabling them to remain productive in the workforce or in family caregiving positions.7-11

Our digital health platforms are essential enablers of care, whether supporting patient monitoring and electronic medical records (EMR) for in-center dialysis patient care, or remotely monitoring and supporting prescription changes for home patients.

Our Sharesource remote patient management platform is the most widely adopted digital health platform for home dialysis, helping manage PD treatments in more than 70 countries. The remote patient management platform allows you to securely view patients’ recently completed home dialysis-related treatment data that is automatically collected after each treatment session. You can then act on this information by remotely adjusting their home device settings without requiring them to make additional trips to the clinic.

Sharesource is featured with our automated peritoneal dialysis systems globally.

For patients who require hemodialysis (HD), we believe they deserve access to the best care possible through our HD monitors and dialyzers.

At the forefront of our therapy offerings for these patients is access to HDx enabled by Theranova. The Theranova Dialyzer was designed to filter a wider range of molecules from the blood than conventional hemodialysis filters, targeting the removal of large middle molecules that may be associated with inflammation and cardiovascular health for ESKD patients.12-14 Its innovative MEDIUM CUT-OFF (MCO) membrane expands the range of solute removed during regular dialysis, while retaining essential proteins at a limited level. This unique cut-off and retention onset profile allows for filtration closer to that of the natural kidney.15-16

By securely sharing data for recently completed home dialysis-related treatment data, Sharesource Remote Patient Management allows healthcare providers to remotely adjust home therapy prescription.

WIth user-friendly features and Sharesource remote patient management, the Homechoice Claria Automated Peritoneal Dialysis System helps patients manage their home peritoneal dialysis (PD) therapy while staying connected to their healthcare providers.

Uniquely offering user-friendly features such as voice guidance and Sharesource remote patient management platform, Amia Automated Peritoneal Dialysis System helps guide patients through home PD therapy and keeps them remotely connected to their healthcare providers.

Featuring the Theranova dialyzer with an innovative membrane to provide an expanded hemodialysis therapy (HDx), HDx enabled by Theranova is a dialysis therapy Baxter is pioneering for patients with end-stage renal disease.

About our U.S. Kidney Care portfolio of products.

Rx Only. For safe and proper use of products mentioned herein, please see the appropriate Operator’s Manual, Instructions for Use or User's Guide. 

MORE THAN 850 MILLION WORLDWIDE HAVE SOME FORM OF KIDNEY DISEASE: HELP RAISE AWARENESS; www. theisn.org, blog. Nov. 27, 2020. Accessed Feb. 2022

NAPRTCS. North American Pediatric Renal Trials and Collaborative Studies. https://web.emmes.com/study/ped/annlrept/annualrept2011.pdf.

Kutner NG, et al Depressed mood, usual activity level, and continued employment after starting dialysis. Clin J Am Soc Nephrol. 2010; 5(11):2040-2045.

Muehrer R, et al Factors affecting employment at initiation of dialysis. Clin J Am Soc Nephrol. 2011;6(3):489-496.

Francois K, et al. Evaluating the benefits of home-based peritoneal dialysis. Int J Nephrol Renovasc Dis. 2014;7:447-455.

Cantekin I, et al. An analysis of caregiver burden of patients with hemodialysis and peritoneal dialysis. Hemodial Int. 2016;20(1):94-97.

Manaf A, et al. Dialysis Provision and Implications of Health Economics on Peritoneal Dialysis Utilization: A Review from a Malaysian Perspective. Intel J of Nephro. 2017;(5):819-629.

Mushi L, et al. The cost of dialysis in low and middle-income countries: a systematic review. BMC Health Serv Res. 2015;(15):50.

Muehrer R, et al. Factors affecting employment at initiation of dialysis. Clin J Am Soc Nephrol. 2011;6(3):489-496.

Kutner N, et al. Depressed mood, usual activity level, and continued employment after starting dialysis. Clin J Am Soc Nephrol. 2010;5(11):2040-2045.

Manera K, et al. Establishing a Core Outcome Set for Peritoneal Dialysis: Report of the SONG-PD (Standardized Outcomes in Nephrology-Peritoneal Dialysis) Consensus Workshop. Am J Kidney Dis. 2020;75(3):404-412.

Chmielewski et al. The Peptidic Middle Molecules: Is Molecular Weight Doing the Trick? Sem Nephrol 2014;34:118–34.

Neirynck N, et al. An update on uremic toxins. Int Urol Nephrol. 2013; 45:139-50.

Duranton F, et al. European Uremic Toxin Work Group. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol. 2012 Jul;23(7):1258-70.

Boschetti-de-Fierro A, et al. MCO membranes: Enhanced Selectivity in High-Flux Class. Scientific Reports 2015; 5:18448

Zweigart C, et al. Medium cut-off membranes – closer to the natural kidney removal function. Int J Artif Organs 2017; 40(7):328-334

©Copyright 2022 Baxter. All rights reserved.